Literature DB >> 21237297

Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.

John Sinclair1, Gergana Metodieva, Dimitra Dafou, Simon A Gayther, John F Timms.   

Abstract

Epithelial ovarian cancer (EOC) is the most common form of gynaecological malignancy in the developed world and has a poor prognosis due to its late detection. Identifying molecular markers of the disease may provide novel approaches to screening and could enable targeted treatment and the design of novel therapies. Although blood is recognized as a highly important source of disease-related biomarkers, the complexity and dynamic range of protein abundance in body fluids has hampered proteomic biomarker discovery and alternative approaches using cell models may be more successful. Herein, we have utilized two cellular models of EOC, where transfer of normal chromosome 18 material into the EOC cell lines TOV-112D and TOV-21G induced in vitro and in vivo suppression of their tumourigenic phenotype. A combination of quantitative two-dimensional difference gel electrophoresis (2D-DIGE) and two-dimensional-liquid chromatography tandem mass spectrometry (2D-LC-MS/MS) with tandem mass tagging (TMT) was employed to examine the whole cell, secreted and crude membrane proteomes of the parental and hybrid cell models to identify differentially expressed proteins as potential markers of tumour suppression. Protein changes of interest were confirmed by immunoblotting in additional hybrid and revertant cell lines where incorporated chromosome 18 material was lost. One candidate marker was also tested in sera from a set of ovarian cancer cases and controls. We have identified a list of promising candidate biomarkers for further testing and functional characterization.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21237297     DOI: 10.1016/j.jprot.2010.12.009

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  12 in total

1.  Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.

Authors:  Zhao-dong Han; Yan-qiong Zhang; Hui-chan He; Qi-shan Dai; Guo-qiang Qin; Jia-hong Chen; Chao Cai; Xin Fu; Xue-cheng Bi; Jian-guo Zhu; Dong-jiang Liao; Xin-peng Lu; Zi-yao Mo; Yun-ping Zhu; Wei-de Zhong
Journal:  Med Oncol       Date:  2012-01-04       Impact factor: 3.064

2.  Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.

Authors:  L Zhou; D Xia; J Zhu; Y Chen; G Chen; R Mo; Y Zeng; Q Dai; H He; Y Liang; F Jiang; W Zhong
Journal:  Clin Transl Oncol       Date:  2014-03-22       Impact factor: 3.405

Review 3.  The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.

Authors:  Hui Wang; Tujin Shi; Wei-Jun Qian; Tao Liu; Jacob Kagan; Sudhir Srivastava; Richard D Smith; Karin D Rodland; David G Camp
Journal:  Expert Rev Proteomics       Date:  2015-12-19       Impact factor: 3.940

4.  A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.

Authors:  N S Sandanayake; J Sinclair; F Andreola; M H Chapman; A Xue; G J Webster; A Clarkson; A Gill; I D Norton; R C Smith; J F Timms; S P Pereira
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

5.  The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing.

Authors:  Sandra G Gonzalez Malagon; Anna N Melidoni; Diana Hernandez; Bilal A Omar; Lyndsey Houseman; Sunil Veeravalli; Flora Scott; Dorsa Varshavi; Jeremy Everett; Yugo Tsuchiya; John F Timms; Ian R Phillips; Elizabeth A Shephard
Journal:  Biochem Pharmacol       Date:  2015-06-04       Impact factor: 5.858

6.  Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Authors:  John F Timms; Elif Arslan-Low; Musarat Kabir; Jenny Worthington; Stephane Camuzeaux; John Sinclair; Joanna Szaub; Babak Afrough; Vladimir N Podust; Evangelia-Ourania Fourkala; Myriam Cubizolles; Florian Kronenberg; Eric T Fung; Aleksandra Gentry-Maharaj; Usha Menon; Ian Jacobs
Journal:  Proteomics Clin Appl       Date:  2014-11-10       Impact factor: 3.494

7.  Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells.

Authors:  Jenny Worthington; Georgia Spain; John F Timms
Journal:  Mol Cell Proteomics       Date:  2017-02-07       Impact factor: 5.911

Review 8.  Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.

Authors:  Agata Swiatly; Szymon Plewa; Jan Matysiak; Zenon J Kokot
Journal:  J Ovarian Res       Date:  2018-10-01       Impact factor: 4.234

9.  An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis.

Authors:  Fu-neng Jiang; Hui-chan He; Yan-qiong Zhang; Deng-Liang Yang; Jie-Hong Huang; Yun-xin Zhu; Ru-jun Mo; Guo Chen; Sheng-bang Yang; Yan-ru Chen; Wei-de Zhong; Wen-Liang Zhou
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

Review 10.  Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.

Authors:  Debasish Paul; Avinash Kumar; Akshada Gajbhiye; Manas K Santra; Rapole Srikanth
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.